FDA Oversight Among Hot Button Issues In 112th Congress
This article was originally published in The Tan Sheet
Health care reform and oversight of FDA remain hot button issues in the 112th Congress, industry advocates say.
You may also be interested in...
The departure may help position the agency now that it faces a Republican majority in the House.
A federal agency's decision against extending a delay on requiring prescriptions for OTC drugs bought with pre-tax medical expense accounts galvanizes the consumer health care product industry's resolve to repeal the change.
Rep. Darrell Issa's questions on what FDA knew about the third-party manufacturer of a product Johnson & Johnson recently recalled reflect the accountability the incoming Oversight and Government Reform Committee chairman will demand from the agency.